The Paediatric Rheumatology INternational Trials Organisation (PRINTO) is a not for profit, non governmental, international research network founded by Alberto Martini and Nicolino Ruperto in 1996. The coordinating centre is based in Genova. PRINTO initially included 14 European countries (85 countries and 578 centres worldwide with 1376 members today), with the goal to foster, facilitate and co-ordinate the development, conduct, analysis, and reporting of multi-centres, international clinical trials and/or outcome standardisation studies in children with paediatric rheumatic diseases (PRD).
Via Gaslini, 5
Genova
Liguria
16147
Italy

Paediatric Rheumatology INternational Trials Organisation (PRINTO)

The Paediatric Rheumatology INternational Trials Organisation (PRINTO) is a not for profit, non governmental, international research network founded by Alberto Martini and Nicolino Ruperto in 1996. Including initially 14 European countries, the organization counts now on the cooperation of 1376 members from 578 centres in 85 countries worldwide. PRINTO has the goal to foster, facilitate and co-ordinate the development, conduct, analysis, and reporting of multi-centres, international clinical trials and/or outcome standardisation studies in children with paediatric rheumatic diseases (PRD).

The coordinating centre is based in Genoa.
To learn more about PRINTO click here
To download the PRINTO brochure click here


IN THE SPOTLIGHT

  • 13-MAR-2024
    European Workshop for Rheumatology Research (EWRR) - 43rd edition
    View...
  • 15-NOV-2021
    pippo
    pippo...
  • 02-JUN-2016
    2nd Global' Conference on Myositis
    Details...
  • 11-FEB-2016
    2016 Classification criteria for MAS published in Ann Rheum Dis
    Paper details...
  • 12-JAN-2016
    Placebo meta-analysis in JIA trials published in Arthritis and Rheumatology
    Paper details...
  • 17-DEC-2015
    23rd PRES Congress in Genoa 28 Sept-1 Oct 2016!
    Details...
  • 30-NOV-2015
    New EMA JIA scientific guideline adopted and published
    Official Guideline...

PROJECTS

  • Liaisons with pharmaceutical companies
    PRINTO is working with pharmaceutical companies as advisor for trials planning, centre selection, data collection, data analysis and interpretation…
    Learn More
  • The STARS Trial
    The comparison of STep-up and step-down therapeutic strategies in childhood ARthritiS trial (STARS) is a new interventional trial aiming to investigate whether an early aggressive therapeutic intervention in children with JIA, based on the initial start of synthetic and biologic DMARDs (Step-down strategy), is superior to an approach based on treatment escalation conducted following the treat-to-target principle (Step-up strategy).
    Learn More
  • Juvenile dermatomyositis trial
    PRINTO designed the present study as a 5-year phase III single-blind, randomized clinical trial in children with newly diagnosed JDM: prednisone (PDN) versus PDN plus methotrexate, versus PDN plus Cyclosporine A…
    Learn More
  • Eurofever Project
    The PReS Autoinflammatory Diseases’ Working Group, in collaboration with PRINTO, set up a a web-based international registry for Autoinflammatory diseases.
    Learn More
  • PharmaChild
    PRINTO and PRES are conducting a pharmacovigilance project which aims at observing children with JIA for 3-10 years undergoing treatment with MTX or biologic agents in order to collect moderate, severe or serious adverse events occurred.
    Learn More
  • EPOCA
    PRINTO is cross-culturally adapting and validating a questionnaire which aims to enable a multidimensional assessment of the disease status and quality of life of children with JIA: the Juvenile Arthritis Multidimensional Assessment Report (JAMAR).
    Learn More
  • ABIRISK
    PRINTO collected samples of children with JIA newly treated with adalimumab, etanercept or tocilizumab within the project ABIRISK, funded by IMI, which has the aim to investigate antidrug antibody formation in the treatment with biopharmaceuticals
    Learn More
  • SHARE Project
    The “Single Hub and Access point for paediatric Rheumatology in Europe” (SHARE) is a European project whose main objective is to improve the quality of care of patients suffering from Paediatric Rheumatic Diseases.
    Learn More
  • CEST-JIA
    The study is aimed to evaluate, through a pragmatic trial, safety and efficacy of switching from the adalimumab and etanercept originator molecules versus their biosimilar competitors and vice-versa in children with JIA in clinical remission on anti-TNF medication.
    Learn More

CERTIFICATIONS

This website uses cookies. By continuing to browse the website you are agreeing to our use of cookies. Learn more   Accept cookies